Pneumonia Testing Market Forecasts to 2030 – Global Analysis By Product Type (Consumables & Reagents, Instruments, Analyzers and Other Product Types), Type (Streptococcus, Legionella, Chlamydophila, Viral Pneumonia, Mycoplasma Pneumonia and Other Types),

Pneumonia Testing Market Forecasts to 2030 – Global Analysis By Product Type (Consumables & Reagents, Instruments, Analyzers and Other Product Types), Type (Streptococcus, Legionella, Chlamydophila, Viral Pneumonia, Mycoplasma Pneumonia and Other Types), Test Type, Method, Technology, End User and by Geography

According to Stratistics MRC, the Global Pneumonia Testing Market is accounted for $655.13 million in 2023 and is expected to reach $1122.77 million by 2030 growing at a CAGR of 8.0% during the forecast period. A vital diagnostic procedure called pneumonia testing is used to determine whether pneumonia—a respiratory infection that inflames the lungs' air sacs—is present. Pneumonia is frequently caused by bacteria, viruses, or fungi. If treatment is not received, it can result in severe respiratory distress. Chest X-rays can be used to see abnormalities in the lungs; blood tests can determine whether an infection is present; and respiratory secretion analysis can pinpoint the cause.

According to a published article by the National Institutes of Health (NIH) in 2022, streptococcus pneumoniae accounts for up to 15.0% of pneumonia cases in the U.S. and 27.0% globally.

Market Dynamics:

Driver:

Population aging and contagious disease risk

One major factor driving the market for pneumonia testing is the demographic shift towards an aging population. There is an increased need for accurate testing procedures because elderly people are more vulnerable to respiratory infections, including pneumonia. Moreover, this demographic factor highlights early detection and the market's responsibility to meet the unique healthcare needs of the aging population.

Restraint:

High initial expenses for cutting-edge diagnostic systems

A barrier to the market for pneumonia testing is the upfront expenses linked to sophisticated diagnostic technologies. Modern instruments like sophisticated imaging technology and molecular diagnostics can be highly expensive up front. Additionally, this could slow down the market penetration of these cutting-edge testing techniques and restrict their adoption, especially in healthcare settings with limited resources.

Opportunity:

Development of platforms for multiplex testing

Pneumonia testing market opportunities are presented by the development of multiplex testing platforms, which can detect multiple pathogens simultaneously. By delivering thorough diagnostic data in a single test and expediting the diagnostic procedure, these platforms increase productivity. Furthermore, discovering co-infections and enhancing overall diagnostic accuracy are two areas in which multiplex testing is especially helpful.

Threat:

Financial limitations in healthcare systems

The widespread adoption of advanced pneumonia testing technologies is threatened by budgetary constraints in healthcare systems. Limited funds may make it more difficult to invest in healthcare personnel's training and to purchase cutting-edge diagnostic tools. Moreover, this may result in unequal access to cutting-edge testing techniques, which could compromise the overall efficacy of pneumonia diagnosis.

Covid-19 Impact:

The COVID-19 pandemic has changed dynamics and priorities in the healthcare sector, which has had a significant effect on the market for pneumonia tests. Pneumonia testing innovation has accelerated due to the pandemic's increased focus on respiratory health and the pressing need for diagnostic solutions. On the other hand, difficulties like supply chain disruptions, fluctuating healthcare spending, and the tremendous demand for testing resources at peak times have also presented formidable obstacles. Additionally, the pandemic has brought to light the critical role that scalable and effective pneumonia testing plays in international health emergencies, and this has forced the industry to innovate and adapt to the changing nature of infectious diseases.

The Viral Pneumonia segment is expected to be the largest during the forecast period

In terms of market share for pneumonia tests, the viral pneumonia segment is projected to hold the largest share. Viral pneumonia has received a lot of attention because of the prevalence of respiratory viruses like influenza and respiratory syncytial virus (RSV) as well as the COVID-19 pandemic, which was primarily caused by the novel coronavirus SARS-CoV-2. Molecular assays, antigen tests, and other diagnostic techniques have advanced as a result of the growth in demand for viral pneumonia-specific diagnostic solutions. Moreover, this segment has become a crucial focal point in the pneumonia testing market due to the contagious nature of respiratory viruses and the need for accurate and quick testing.

The Diagnostic Laboratories segment is expected to have the highest CAGR during the forecast period

In the market for pneumonia testing, the diagnostic laboratory segment is anticipated to grow at the highest CAGR. Diagnostic laboratories, which provide a variety of diagnostic modalities like imaging studies, blood tests, and molecular diagnostics, are essential to the provision of thorough and specialized testing services for pneumonia. Diagnostic laboratories have grown as a result of improvements in diagnostic technologies and the growing need for quick and accurate testing for pneumonia. Additionally, these facilities are frequently at the forefront of adopting cutting-edge diagnostic techniques and are outfitted to efficiently handle a high volume of tests.

Region with largest share:

The region of North America is projected to have the largest market share for pneumonia testing. The region's prominence is attributed to its strong healthcare infrastructure, cutting-edge diagnostic technologies, and proactive management of infectious diseases. Furthermore, the demand for pneumonia testing is driven by favorable reimbursement policies, heightened awareness, and a higher prevalence of respiratory infections in North America.

Region with highest CAGR:

In the market for pneumonia testing, the Asia-Pacific region is projected to have the highest CAGR. The rising incidence of respiratory infections, the aging population, the increased spending on healthcare infrastructure, and the increased emphasis on enhancing healthcare accessibility in Asia-Pacific nations are some of the causes of this. Moreover, the high growth is a result of the region's growing economies, improvements in healthcare technologies, and increased public awareness of the value of early diagnosis.

Key players in the market

Some of the key players in Pneumonia Testing market include Danaher , Abbott, F. Hoffmann-La Roche Ltd., Beckton and Dickinson Company, Cepheid, Biomerieux SA, Hologic Inc, Luminex Corporation, Meridian Bioscience, Inc., Bio Rad laboratories, OpGen, Quidel Corporation, AdvanDx, Thermo Fisher Scientific Inc., Beckman Coulter , Siemens Healthcare GmbH and Quest Diagnostics Incorporated .

Key Developments:

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

In September 2023, Hologic and Bayer today announced an international partnership focused on improving breast cancer detection. The companies teamed up to deliver contrast-enhanced mammography (CEM) solutions across Europe, Canada and Asia Pacific. CEM, a highly sensitive, relatively low-cost breast imaging modality, combines digital mammography with contrast agent administration. It supports breast cancer diagnosis and guides treatment decisions.

In August 2023, Science and medical technology firm Danaher announced Monday that it has entered into an agreement to acquire Abcam, a Cambridge, U.K.-based supplier of antibodies, reagents, biomarkers, and assays. Under the agreement, Danaher will acquire all outstanding Abcam shares for $24 per share in cash, with a total enterprise value of approximately $5.7 billion, including Abcam’s assumed debts and net of acquired cash.

Product Types Covered:
• Consumables & Reagents
• Instruments
• Analyzers
• Other Product Types

Types Covered:
• Streptococcus
• Legionella
• Chlamydophila
• Viral Pneumonia
• Mycoplasma Pneumonia
• Other Types

Test Types Covered:
• Blood Test
• Imaging Test
• Sputum Test
• Urine Test
• Other Test Types

Methods Covered:
• Molecular Diagnostics
• Point of Care Testing
• Immunodiagnostics
• Other Methods

Technologies Covered:
• Enzyme Linked Immunosorbant Assay
• Immunofluoroscence
• Western Blot
• Polymerase Chain Reaction
• Imunohistochemistry
• Other Technologies

End Users Covered:
• Hospitals & Clinics
• Diagnostic Laboratories
• Homecare
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements Show more